Lipfendra (Enlicitide): The First Oral PCSK9 Inhibitor for High Cholesterol - What NYC Patients and Prescribers Should Know
On July 16, 2026, the FDA approved Lipfendra (generic name: enlicitide) - the first oral PCSK9 inhibitor for lowering LDL cholesterol. Manufactured by Merck, it is a once-daily 20 mg tablet indicated for adults with high cholesterol, including an inherited form called heterozygous familial hypercholesterolemia (HeFH).
Until now, PCSK9 inhibitors like Repatha (evolocumab) and Praluent (alirocumab) have been available only as injections. Lipfendra is the first pill in this powerful class of cholesterol-lowering medications. For patients who have been unable or unwilling to inject, this changes what is possible.
Here is what NYC patients and prescribers should know.
What Is Lipfendra?
Lipfendra is a novel macrocyclic peptide that binds to PCSK9 (proprotein convertase subtilisin/kexin type 9) and blocks its interaction with LDL receptors on liver cells. This allows the liver to clear more low-density lipoprotein cholesterol (LDL-C) - the "bad" cholesterol - from the bloodstream.
Because it works upstream of statin therapy, Lipfendra is used as an adjunct to diet, exercise, and maximally tolerated statin therapy - not as a replacement.
Who Is Lipfendra For?
Lipfendra is FDA-approved for adults with primary hypercholesterolemia, including HeFH, whose LDL-C remains above goal despite a maximally tolerated statin. In simple terms:
- Adults with high LDL cholesterol who need additional lowering beyond what a statin achieves
- Adults with heterozygous familial hypercholesterolemia - an inherited form of high cholesterol that is often harder to control with statin alone
- Patients who cannot tolerate, or prefer to avoid, injectable PCSK9 inhibitors
How Well Does It Work?
Lipfendra's approval was based on two Phase 3 trials in the CORALreef clinical program:
CORALreef Lipids
In adults with high cholesterol and elevated cardiovascular risk who were already on a maximally tolerated statin, Lipfendra reduced LDL-C by 56% compared to placebo at week 24.
CORALreef HeFH
In adults with heterozygous familial hypercholesterolemia, Lipfendra reduced LDL-C by 59% compared to placebo at week 24.
Both trials also showed meaningful reductions in other important markers: non-HDL cholesterol dropped by approximately 54%, and apolipoprotein B (ApoB) by approximately 50%. These reductions are in the same range as what the injectable PCSK9 inhibitors achieve - which is notable for a pill.
What Patients Should Know
- Take one 20 mg tablet by mouth once daily, with or without food.
- Continue your statin and any other cholesterol medications your provider has prescribed unless they tell you otherwise.
- Continue diet and exercise. Lipfendra is meant to work alongside heart-healthy lifestyle changes, not replace them.
- Do not stop your statin or change your cholesterol regimen without first talking to your healthcare provider.
Common Side Effects
Across the CORALreef trials, Lipfendra was generally well tolerated with a safety profile similar to placebo. The most commonly reported side effects (versus placebo) were:
- Diarrhea (approximately 7% vs 2%)
- Dizziness (approximately 9% vs 4%)
Discontinuation rates in the trials were similar to placebo. As always, patients should discuss their full medical history and current medications with their prescriber before starting.
For Prescribers: Clinical Snapshot
Class
Oral macrocyclic peptide PCSK9 inhibitor.
Indication
Adjunct to diet and maximally tolerated statin therapy to reduce LDL-C in adults with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).
Dose
20 mg orally once daily. Tablets. Take with or without food.
Mechanism
Novel macrocyclic peptide that binds PCSK9 and blocks its interaction with hepatic LDL receptors, increasing LDL receptor recycling and hepatic LDL clearance.
Efficacy
Phase 3 CORALreef Lipids: -56% LDL-C vs placebo at week 24. Phase 3 CORALreef HeFH: -59% LDL-C vs placebo at week 24. Additional reductions in non-HDL-C (~54%) and ApoB (~50%).
Where It Fits
For patients on maximally tolerated statin therapy who still have not achieved LDL-C goals, Lipfendra offers a once-daily oral option previously unavailable in the PCSK9 class. It may be particularly useful for patients who have declined or discontinued injectable PCSK9 therapy (Repatha, Praluent) due to injection burden, cost, or preference.
How Lipfendra Compares to Injectable PCSK9 Inhibitors
| Medication | Route | Typical Dosing Schedule | Class |
|---|---|---|---|
| Lipfendra (enlicitide) | Oral tablet | Once daily | Macrocyclic peptide PCSK9 inhibitor |
| Repatha (evolocumab) | Subcutaneous injection | Every 2 weeks or monthly | Monoclonal antibody PCSK9 inhibitor |
| Praluent (alirocumab) | Subcutaneous injection | Every 2 weeks or monthly | Monoclonal antibody PCSK9 inhibitor |
All three lower LDL-C substantially and are indicated as adjuncts to statin therapy. The choice among them depends on patient preference, insurance coverage, tolerability, and clinical judgment.
Frequently Asked Questions
Is Lipfendra the same as Repatha or Praluent?
No. Lipfendra, Repatha, and Praluent all block PCSK9, but Lipfendra is an oral tablet while Repatha and Praluent are injections. Lipfendra is also a different type of molecule - a macrocyclic peptide, not a monoclonal antibody. All three work in the same general way to help the liver clear more LDL cholesterol.
Do I still need to take my statin?
Yes, unless your prescriber tells you otherwise. Lipfendra is approved as an add-on to your maximally tolerated statin therapy, not a replacement. Statins remain the foundation of cholesterol treatment.
When will Lipfendra be widely available?
Lipfendra was FDA-approved on July 16, 2026. Availability at pharmacies and coverage by individual insurance plans will roll out over the coming weeks and months. Your pharmacy can tell you the current status.
How much will Lipfendra cost?
Pricing and insurance coverage details from Merck are being announced. As with other specialty cholesterol medications, manufacturer copay savings programs and patient assistance may be available. Your pharmacy can help you check what applies to your situation.
The Bottom Line
For millions of adults whose LDL cholesterol remains too high despite statin therapy - and for those with inherited high cholesterol who need additional treatment - Lipfendra offers something new: a once-daily pill that lowers LDL as effectively as injectable PCSK9 inhibitors. It is a meaningful addition to the toolkit for cardiovascular disease prevention.
If you or your patients have questions about how Lipfendra may fit into a cholesterol treatment plan, talk to your healthcare provider. Our pharmacists at 79th Street Pharmacy are also here to answer questions about the medication itself, current availability, and savings programs as they become known.
This information is provided as an educational resource. Prescription required. Please consult your healthcare provider to determine if Lipfendra is appropriate for you.